/ Published in 2013, Publication

Safety and Immunogenicity of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine

Safety and Immunogenicity of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine: A Randomized Trial in 10-25-Year-Old HIV-Seronegative African Girls and Young Women.

Sow PS, Watson-Jones D, Kiviat N, Changalucha J, Mbaye JD, Brown J, Bousso K, Kavishe B, Andreasen A, Toure M, Kapiga S, Mayaud P, Hayes R, Lebacq M, Herazeh M, Thomas F, Descamps D.

J Infect Dis 2013; 207:1753-63.

PMID:23242542

PMCID:PMC3636781

DOI:10.1093/infdis/jis619

Related citation

What you can read next

Immune Activation in the Female Genital Tract: Expression Profiles of Soluble Proteins in Women at High Risk for HIV Infection.
How long-distance truck drivers and villagers in rural southeastern Tanzania think about heterosexual anal sex: a qualitative study.
Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial.